期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

一种新糖肽抗生素LY333328的抗菌活性与作用机制 被引量：1

在线阅读 下载PDF
导出
摘要 对新的糖肽抗生素药物———LY3 3 3 3 2 8的抑菌杀菌活性、机理、化学结构修饰的影响进行了综述。LY3 3 3 3 2
作者 罗清平 沈亚领 迟莉丽 魏东芝
机构地区 华东理工大学生物化学研究所生物反应器工程国家重点实验室 山东中医药大学附属医院
出处 《国外医药（抗生素分册）》 CAS 2004年第5期221-225,共5页 World Notes on Antibiotics
关键词 糖肽抗生素 LY333328 抗菌活性 作用机制 万古霉素 病原菌
分类号 R978.1 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1程元荣,郑卫.微生物生物活性物质的研究进展[J].中国抗生素杂志,2002,27(10):632-640. 被引量：25
  • 2Zelenitsky SA, Karlowsky JA,Nicas TN. Time - kill curves for a semisynthetic glycopeptide,LY333328,against vancomycin-susceptible and vancomycin - resistant Enterococcus faecium strain [J]. Antimicrob Agents Chemother,1997,41(6):1407
  • 3Le Tourneau DL, Hobbs JN, Allen NE. Molecular interactions of Ly264826 and its p - chlorobenzyl derivative[R]. Woshng ton: LY191145, with dipeptidyl and didepsipeptidyl ligands, abstr. F250, In program and abstracts of the 35th inter Science conference on
  • 4Coyle EA, Rybak MJ. Activity of oritavancin (LY333328),an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model [J]. Antimicrob Agents Chemother ,2001,45(3) :
  • 5Rarenti F, Beretta G, Berti M, et al. Teichomycins new antibiotics from Actinoplanes leichomyceticus nov sp I, description of the producer strain, fermentation studies and biological propert [J]. J Antibiot, 1978,31: 276
  • 6Steele-Moore L,Maclntosh A ,Furdess K.In vivo activity of an investigational glycopeptide antibiotic LY333328[R].woshington: In Abstracts of the 96th General Meeting of the American Society for Microbiology, 1996:143
  • 7Hershberger E,Jeffrey R,Tabitha A,et al.Evaluation of bactericidal activities of LY333328,vancomycin teicoplanin, ampicilin-sulbactam,trovafloxacin,and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin - i
  • 8Merclep RC,Heather H,Houlihan J,et al.Pharmacodynamic evaluation of a new glycopeptide , LY333328.and In vitro activity against Staphylococcus aureus and Enterococcus faecium [J]. Antimicrob Agents Chemother,1997,41(6): 1307
  • 9Cooper RDG, Snyder NJ, Zweifel MJ, et al. Reductive alkylation of glycopeptide antibiotics. synthesis and antibacterial activity[J].JAntibiot,1996,49:575
  • 10Biavasco F,Vignaroli C,Lupidi R,et al.In vitro antibacterial activity of LY333328,a new semisynthetic glycopeptide [J].Antimicrob Agents Chemother,1997,41(10):2165

二级参考文献53

  • 1程元荣.微生物产生的免疫抑制剂[J].中国抗生素杂志,1996,21(A00):24-35. 被引量：14
  • 2Stefansha A L, Coates N J, Mensah L M, et al. SB-21938,a novel tyrosyl tRNA synthelase inhibitor from a Micromonospors sp. I. Fermentation, isolation and properties[J]. J Antibiot ,2000;53(4):345
  • 3Canedo L M, Puents J L F. Perez B J, et al. IB-96212, a novel cytotoxic macrolide produced by a marine Micromonospora. Ⅱ . Phsico-chemical properties and structure determination [J]. J Antibiot ,2000;53(5):479
  • 4Canedo H L M, Fuente B A, Perez B J, et al. 4'-NMethyl-5 '- hydroxystaurosporine and 5 '-Hydroxystaurosporine, new indolocashazole alkaloids from a marine Micromonospora sp. strain [J]. J Antibiot ,2000;53(9) :895
  • 5Yeo W H, Yun B S, Kim S S, et al. GTRI-02, a new liquid peroxidation inhibitor from Micromonospora sp. SA246[J ]. J Antibiot, 1998;51(10):952
  • 6Cavalheri B, Pagani H, Votpe G. et al. A-16686, a new antibiotic from Actinoplanes. I . Fermention, isolation and preliminary physico-chemical characteristics [J]. JAntibiot,1984; 37 (4): 309
  • 7Pallanza R, Berti M, Scott R, et al. A-16686, a new antibiotic from Actinoplanes. Ⅱ. Biological properties [J]. J Antibiot, 1984; 37(4): 318
  • 8Ciabatti R, Kettenring J K, Winters G, et al. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. Ⅲ.Structure elucidation [J]. J Antibiot, 1989; 42 (2): 254
  • 9Ikemoto T, Matsunaga H, Konishi K, et al. Aculeximycin,a new antibiotic from Streptosporangium alhidum. I. Taxonomy of producing organisim and fermentation [J]. J Antibiot, 1983;36(9): 1093
  • 10Murata H, Suauki, K Tahayash T, et al. Structural elucidation of aculeximycin. Ⅲ. Planar structure of aculeximycin,belonging to a new class of macrolide antibiotics [J]. J Antibiot, 1995; 48 (8): 838

共引文献24

同被引文献25

  • 1BHAVNANI SM, OWEN JS, LOUTIT JS, et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects [ J ]. Diagn Microbiol Infect Dis,2004,50(2 ) :95 - 102.
  • 2FETTERLY GJ, ONG CM, BHAVNANI SM, et al. Phannacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose[ J]. Antimicrob Agents Chemother,2005,49 ( 1 ) : 148 - 152.
  • 3WASILEWSKI M, DISCH D, MCGILL J, et al. Equivalence of shorter course therapy with orltavancin vs. vancomycin/cephalexin in complicated skin-skin structure infections(cSSSI)[J]. Antimicrob Agents Chemother ,2001 ,abstr: UL-18.
  • 4GIAMARELLOU H, O'RIORDAN W, HARRIS H, et al. Phase 3 trial comparing 3 -7 days of oritavancin vs 10 - 14 days of vancomycin/cephalexin in the treatment of patients with complicated skin and skin structure infections(cSSSI) [ J]. Antimicrob Agents Chemother, 2003, abstr: L-739 a.
  • 5RARENTI F, BERETTA G, BERTI M, et al. Teichomycins new antibiotics from Actinoplanes leichomyceticus nov sp I, description of the producer strain, fermentation studies and biological propert [ J]. J Antibiot, 1978,31 (4) :276 - 283.
  • 6BEAUREGARD DA,WILLIAMS DH, GWYNN MN, et al. Dimerization and membrane anchom in the extracellular targeting of vancomycin group antibiotics[ J]. A ntimlcrob Agents Chemother , 1995,39(3 ) :781 -785.
  • 7LE TOURNEAU DL,HOBBS JN,ALLEN NE. Molecular interactions of Ly264826 and its p-chlorobenzyl derivative [ C ]// LY191145, with dipeptidyl and didepsipeptidyl ligands, abstr.F250, In program and abstracts of the 35th inter Science conference on antimicrobial agents and chemotherapy American society for microbiology, Woshington, 1995 : 156.
  • 8NICAS TI, MULLEN DL, FLOKOWITSCH JE. Semisynthetic glycopeptide antibiotics derived from L Y264826 active against vancomycin-resistant enterococci [ J ]. Antimicrob Agents Chemother, 1996,40 ( 9 ) : 2194 - 2199.
  • 9COYLE EA, RYBAK MJ. Activity of oritavancin ( L Y333328), an investigational glycopeptide, compared to that of vancomycin against muhidrug-resistant Streptococcus pneumoniae in an in vitro pharmacodynamic model[ J ]. A ntimicrob Agent Chemother ,2001, 45 (3) :706 - 709.
  • 10FEKETY E, IN FL, MANDELL J E, et al. Principles and practice of infectious diseases[M]. New York: 4thed Churchill Livingston, 1995:346.

引证文献1

二级引证文献3

国外医药（抗生素分册）
2004年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部